Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Bayer is transforming pharmaceutical research into women's health

2.

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

3.

Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds

4.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

5.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot